Caesarea, Israel – October 13, 2026 -- IceCure Medical (Nasdaq: ICCM) reported 12-month objective response rates of 97.5% among 40 breast cancer patients treated with ProSense® cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands.

Raleigh – October 13, 2026 -- Ledger Run, a clinical trial financial management provider, has appointed former Cytel and Oracle product executive Anne Pelz as Vice President of Product and is increasing R&D spending to build an AI-powered, end-to-end financial platform.

Boston – October 13, 2026 -- Red Queen Bio PBC has recruited Ian Watson, a former Deputy Assistant Secretary of War for Chemical, Biological, Radiological and Nuclear (CBRN) Defense, to lead its government affairs strategy as the AI biosecurity company expands its work with federal buyers.

Research Triangle Park – October 13, 2026 -- IQVIA has selected four Veeva applications (CTMS, eTMF, Study Startup and Site Connect) as enterprise standards for its clinical development studies, extending a partnership that previously covered Veeva's EDC.

IQVIA and Veeva widen the clinical technology tie-up beyond EDC

IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced the expansion on Oct. 13, 2026. The companies say the combined offering is intended to raise trial speed and efficiency, strengthen site centricity and improve decision-making.

London – October 13, 2026 -- Mothers in the U.K., Sweden and France report having 2-2.1 children on average, against the 2.8-2.9 they say they want, according to new data from the IVI Institute Fertility Barometer. The study surveyed 24,074 women aged 19 to 49 across nine countries.

IVI Institute, formerly IVI RMA Global, released the regional findings as it consolidates its clinics under a single name. Clinics will operate as IVI Fertility, Livio and Create Fertility as members of IVI Institute.

MADRID – October 13, 2026 -- An estimated 6.8 million women across nine countries are experiencing infertility right now, according to the inaugural IVI Institute Fertility Barometer, which also finds that 36% of women with a target age for starting a family had their first child later than desired. IVI Institute, formerly IVI RMA Global, released the study alongside a group-wide rebrand that unites its clinic networks.

Dallas – October 13, 2026 -- Koya Medical will put its CEO and CFO in front of investors at two conferences on consecutive days, October 19 and 20, 2026, as the vascular disease device maker promotes the commercial momentum of its portfolio.

CEO Doraiswamy presents at Goldman Sachs in New York on October 19

Andy Doraiswamy, Koya's chief executive, will present on Monday, October 19, 2026, at the Goldman Sachs Healthcare Private Company Conference. The session takes place at the Goldman Sachs Client Center in New York City.

Seoul – October 12, 2026 -- South Korea's GCCL and LabConnect signed a memorandum of understanding on October 12 to link their North American and Asia-Pacific (APAC) central laboratory capabilities for joint sales and project execution in global clinical trials.

Partners formalize a relationship spanning more than 20 years

The agreement builds on a collaboration that has run for more than 20 years. It aims to improve the operational efficiency of global trial projects by combining each company's regional expertise. Financial terms were not disclosed.

Philadelphia – October 12, 2026 -- Breakthrough T1D, formerly JDRF, closed its inaugural Clinical & Research Congress after more than 80 sessions and scheduled the 2027 edition for Washington, D.C., October 15-17, 2027.

The congress ran October 9-11, 2026, in Philadelphia. It brought together clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience and community advocates.

Friendswood – October 12, 2026 -- Management recommendations changed in line with TissueCypher risk classifications for 96% of patients in a multi-center Barrett's esophagus cohort, according to data Castle Biosciences (Nasdaq: CSTL) is presenting at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Oct. 9-14.

The company is presenting three studies: two case reports and one multi-center cohort study. All three examine whether the molecular test adds risk information beyond histopathology.